Domain Therapeutics Presents Novel Data Addressing Key Challenges in Oncology at AACR 2025
- Phase I clinical results of DT-9081, an EP4 receptor antagonist, allowed selection of recommended Phase II dose (RP2D) for further development in solid tumors
- Preclinical data of DT-7012 position this Treg depleting anti-CCR8 antibody as a highly differentiated candidate for clinical development
- Preclinical findings demonstrate high potential of the PAR2 biased negative allosteric modulator (NAM) program to potentiate anti-tumor immunity
Strasbourg, France – Montreal, Canada – Boston, United States, April 30, 2025: Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announces new clinical and preclinical data for its key oncology programs DT-9081 and DT-7012, and preclinical insights on its PAR2 biased NAM program at the American Association for Cancer Research (AACR) in Chicago, USA.
